Experts forum

Intestinal microenvironment as an idea in treatment of chronic constipation

Expand

Received date: 2020-01-10

  Online published: 2020-04-25

Cite this article

TIAN Hongliang, LI Ning . Intestinal microenvironment as an idea in treatment of chronic constipation[J]. Journal of Surgery Concepts & Practice, 2020 , 25(02) : 98 -101 . DOI: 10.16139/j.1007-9610.2020.02.002

References

[1] Bharucha AE, Pemberton JH, Locke GR 3rd. American Gastroenterological Association technical review on constipation[J]. Gastroenterology, 2013, 144(1):218-238.
[2] Rao SS, Rattanakovit K, Patcharatrakul T. Diagnosis and management of chronic constipation in adults[J]. Nat Rev Gastroenterol Hepatol, 2016, 13(5):295-305.
[3] Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review[J]. Am J Gastroenterol, 2004, 99(4):750-759.
[4] Belsey J, Greenfield S, Candy D, et al. Systematic review: impact of constipation on quality of life in adults and children[J]. Aliment Pharmacol Ther, 2010, 31(9):938-949.
[5] Rao SS, Seaton K, Miller MJ, et al. Psychological profiles and quality of life differ between patients with dyssynergia and those with slow transit constipation[J]. J Psychosom Res. 2007, 63(4):441-449.
[6] Dennison C, Prasad M, Lloyd A, et al. The health-related quality of life and economic burden of constipation[J]. Pharmacoeconomics, 2005, 23(5):461-476.
[7] Rao SS. Constipation: evaluation and treatment of colonic and anorectal motility disorders[J]. Gastroenterol Clin North Am, 2007, 36(3):687-711.
[8] Locke GR 3rd, Zinsmeister AR, Fett SL, et al. Overlap of gastrointestinal symptom complexes in a US community[J]. Neurogastroenterol Motil, 2005, 17(1):29-34.
[9] American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America[J]. Am J Gastroenterol, 2005, 100(Suppl 1):S1-S4.
[10] Tack J, Muller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation--a European perspective[J]. Neurogastroenterol Motil, 2011, 23(8):697-710.
[11] Kamm MA, Mueller-Lissner S, Wald A, et al. Oral bisacodyl is effective and well-tolerated in patients with chronic constipation[J]. Clin Gastroenterol Hepatol, 2011, 9(7):577-583.
[12] Gerritsen J, Smidt H, Rijkers GT, et al. Intestinal microbiota in human health and disease: the impact of probio-tics[J]. Genes Nutr, 2011, 6(3):209-240.
[13] Kirgizov IV, Sukhorukov AM, Dudarev VA, et al. Hemostasis in children with dysbacteriosis in chronic constipation[J]. Clin Appl Thromb Hemost, 2001, 7(4):335-338.
[14] Parthasarathy G, Chen J, Chen X, et al. Relationship between microbiota of the colonic mucosa vs feces and symptoms, colonic transit, and methane production in female patients with chronic constipation[J]. Gastroentero-logy, 2016, 150(2):367-379.
[15] Vandeputte D, Falony G, Vieira-Silva S, et al. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates[J]. Gut, 2016, 65(1):57-62.
[16] Hadizadeh F, Walter S, Belheouane M, et al. Stool frequency is associated with gut microbiota composition[J]. Gut, 2017, 66(3):559-560.
[17] Rebollar E, Arruebo MP, Plaza MA, et al. Effect of lipopolysaccharide on rabbit small intestine muscle contractility in vitro: role of prostaglandins[J]. Neurogastroenterol Motil, 2002, 14(6):633-642.
[18] Rondeau MP, Meltzer K, Michel KE, et al. Short chain fatty acids stimulate feline colonic smooth muscle contraction[J]. J Feline Med Surg, 2003, 5(3):167-173.
[19] Reigstad CS, Salmonson CE, Rainey JF 3rd, et al. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells[J]. Faseb J, 2015, 29(4):1395-1403.
[20] Zhu Y, Li F, Guo GL. Tissue-specific function of farnesoid X receptor in liver and intestine[J]. Pharmacol Res, 2011, 63(4):259-265.
[21] Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function[J]. Clin Gastroenterol Hepatol, 2010, 8(2):159-165.
[22] Jones BV, Begley M, Hill C, et al. Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome[J]. Proc Nati Acad Sci U S A, 2008, 105(36):13580-13585.
[23] Hofmann AF, Eckmann L. How bile acids confer gut mucosal protection against bacteria[J]. Proc Nati Acad Sci U S A, 2006, 103(12):4333-4334.
[24] Peregrin AT, Ahlman H, Jodal M, et al. Involvement of serotonin and calcium channels in the intestinal fluid secretion evoked by bile salt and cholera toxin[J]. Br J Pharmacol, 1999, 127(4):887-894.
[25] Kidd M, Modlin IM, Gustafsson BI, et al. Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants[J]. Am J Physiol Gastrointest Liver Physiol, 2008, 295(2):G260-G272.
[26] Camilleri M. Bile Acid diarrhea: prevalence, pathogenesis, and therapy[J]. Gut Liver, 2015, 9(3):332-339.
[27] Bunnett NW. Neuro-humoral signalling by bile acids and the TGR5 receptor in the gastrointestinal tract[J]. J Phy-siol, 2014, 592(14):2943-2950.
[28] Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis[J]. Cell, 2015, 161(2):264-276.
[29] Tan J, McKenzie C, Potamitis M, et al. The role of short-chain fatty acids in health and disease[J]. Adv Immunol, 2014, 121:91-119.
[30] Koh A, de Vadder F, Kovatcheva-Datchary P, et al. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites[J]. Cell, 2016, 165(6):1332-1345.
[31] Guilloteau P, Martin L, Eeckhaut V, et al. From the gut to the peripheral tissues: the multiple effects of butyrate[J]. Nutr Res Rev, 2010, 23(2):366-384.
[32] Flint HJ, Scott KP, Louis P, et al. The role of the gut microbiota in nutrition and health[J]. Nat Rev Gastroenterol Hepatol, 2012, 9(10):577-589.
[33] 李宁, 田宏亮. 菌群移植在肠道微生态相关疾病中的研究进展与思考[J]. 中华胃肠外科杂志, 2017, 20(10):19-23.
[34] Li T, Lu X, Yang X. Stachyose-enriched alpha-galacto-oligosaccharides regulate gut microbiota and relieve constipation in mice[J]. J Agric Food Chem, 2013, 61(48):11825-11831.
[35] Quigley EM. The enteric microbiota in the pathogenesis and management of constipation[J]. Best Pract Res Clin Gastroenterol, 2011, 25(1):119-126.
[36] Jennings A, Davies GJ, Costarelli V, et al. Dietary fibre, fluids and physical activity in relation to constipation symptoms in pre-adolescent children[J]. J Child Health Care, 2009, 13(2):116-127.
[37] López Román J, Martínez Gonzálvez AB, Luque A, et al. The effect of a fibre enriched dietary milk product in chronic primary idiopatic constipation[J]. Nutr Hosp, 2008, 23(1):12-19.
[38] Derrien M, van Hylckama Vlieg JE. Fate, activity, and impact of ingested bacteria within the human gut microbiota[J]. Trends Microbiol, 2015, 23(6):354-366.
[39] Ding C, Ge X, Zhang X, et al. Efficacy of synbiotics in patients with slow transit constipation: a prospective randomized trial[J]. Nutrients, 2016, 8(10).pii:E605.
[40] Dimidi E, Christodoulides S, Fragkos KC, et al. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials[J]. Am J Clin Nutr, 2014, 100(4):1075-1084.
[41] Marteau P, Cuillerier E, Meance S, et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study[J]. Aliment Pharmacol Ther, 2002, 16(3):587-593.
[42] Waller PA, Gopal PK, Leyer GJ, et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults[J]. Scand J Gastroenterol, 2011, 46(9):1057-1064.
[43] Zhao Y, Yu YB. Intestinal microbiota and chronic constipation[J]. Springerplus, 2016, 5(1):1130.
[44] Zhang FM, Luo W, Shi Y, et al. Should we Standardize the 1,700-year-old fecal microbiota transplantation?[J]. Am J Gastroenterol, 2012, 107(11):1755.
[45] Eiseman B, Silen W, Bascom GS, et al. Fecal enema as an adjunct in the treatment of pseudomem branous entemcolitis[J]. Surgery, 1958, 44(5):854-859.
[46] Borody TJ, George L, Andrews P, et al. Bowel-flora alte-ration: a potential cure for inflammatory bowel disease and irritable bowel syndrome[J]. Med J Aust, 1989, 150(10):604.
[47] Tian H, Ge X, Nie Y, et al. Fecal microbiota transplantation in patients with slow-transit constipation: A rando-mized, clinical trial[J]. PLoS One, 2017, 12(2):e0171308.
[48] 李宁, 田宏亮, 陈启仪, 等. 菌群移植治疗肠道疾病2010例疗效分析[J]. 中华胃肠外科杂志, 2019, 22(9):861-868.
[49] 田宏亮, 丁超, 马春联, 等. 粪菌胶囊治疗慢传输型便秘15例临床疗效分析[J]. 中国实用外科杂志, 2016, 36?(4):430-432.
[50] Camilleri M, Piessevaux H, Yiannakou Y, et al. Efficacy and safety of prucalopride in chronic constipation: an integrated analysis of six randomized, controlled clinical trials[J]. Dig Dis Sci, 2016, 61(8):2357-2372.
[51] Pamer EG. Fecal microbiota transplantation: effectiveness, complexities, and lingering concerns[J]. Mucosal Immunol, 2014, 7(2):210-214.
Outlines

/